Pre-clinical studies of epigenetic therapies targeting histone modifiers in lung cancer

Kenneth Huffman, Elisabeth D. Martinez

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Treatment options for lung cancer patients have been generally limited to standard therapies or targeted interventions which involve a small number of known mutations. Although the targeted therapies are initially successful, they most often result in drug resistance, relapse, and mortality. We now know that the complexity of lung cancer comes not only from genomic changes, but also from aberrant epigenetic regulatory events. Epigenetic therapies have shown promise as single agents in the treatment of hematological malignancies but have yet to meet this expectation in solid tumors thus fostering researchers to pursue new approaches in the development and use of epigenetic interventions. Here, we review some recent pre-clinical findings involving the use of drugs targeting histone modifying enzymes both as single agents and as co-therapies against lung cancer. A greater understanding of the impact of these epigenetic compounds in lung cancer signaling is needed and further evaluation in vivo is warranted in several cases based on the pre-clinical activity of a subset of compounds discussed in this review, including drugs co-targeting HDACs and EGF receptor, targeting Brd4 and targeting Jumonji histone demethylases.

Original languageEnglish (US)
Article numberArticle 235
JournalFrontiers in Oncology
Volume3 SEP
DOIs
StatePublished - 2013

Fingerprint

Epigenomics
Histones
Lung Neoplasms
Drug Delivery Systems
Therapeutics
Histone Demethylases
Foster Home Care
Hematologic Neoplasms
Epidermal Growth Factor Receptor
Drug Resistance
Clinical Studies
Research Personnel
Recurrence
Mutation
Mortality
Enzymes
Neoplasms

Keywords

  • BRD4
  • Epigenetic therapeutics
  • EZH2 inhibitors
  • HDAC inhibitors
  • Jumonji demethylases
  • Jumonji inhibitors
  • Lung cancer
  • Pre-clinical studies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pre-clinical studies of epigenetic therapies targeting histone modifiers in lung cancer. / Huffman, Kenneth; Martinez, Elisabeth D.

In: Frontiers in Oncology, Vol. 3 SEP, Article 235, 2013.

Research output: Contribution to journalArticle

@article{e81430c2124f4d089b299ebc0b9d5e04,
title = "Pre-clinical studies of epigenetic therapies targeting histone modifiers in lung cancer",
abstract = "Treatment options for lung cancer patients have been generally limited to standard therapies or targeted interventions which involve a small number of known mutations. Although the targeted therapies are initially successful, they most often result in drug resistance, relapse, and mortality. We now know that the complexity of lung cancer comes not only from genomic changes, but also from aberrant epigenetic regulatory events. Epigenetic therapies have shown promise as single agents in the treatment of hematological malignancies but have yet to meet this expectation in solid tumors thus fostering researchers to pursue new approaches in the development and use of epigenetic interventions. Here, we review some recent pre-clinical findings involving the use of drugs targeting histone modifying enzymes both as single agents and as co-therapies against lung cancer. A greater understanding of the impact of these epigenetic compounds in lung cancer signaling is needed and further evaluation in vivo is warranted in several cases based on the pre-clinical activity of a subset of compounds discussed in this review, including drugs co-targeting HDACs and EGF receptor, targeting Brd4 and targeting Jumonji histone demethylases.",
keywords = "BRD4, Epigenetic therapeutics, EZH2 inhibitors, HDAC inhibitors, Jumonji demethylases, Jumonji inhibitors, Lung cancer, Pre-clinical studies",
author = "Kenneth Huffman and Martinez, {Elisabeth D.}",
year = "2013",
doi = "10.3389/fonc.2013.00235",
language = "English (US)",
volume = "3 SEP",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Pre-clinical studies of epigenetic therapies targeting histone modifiers in lung cancer

AU - Huffman, Kenneth

AU - Martinez, Elisabeth D.

PY - 2013

Y1 - 2013

N2 - Treatment options for lung cancer patients have been generally limited to standard therapies or targeted interventions which involve a small number of known mutations. Although the targeted therapies are initially successful, they most often result in drug resistance, relapse, and mortality. We now know that the complexity of lung cancer comes not only from genomic changes, but also from aberrant epigenetic regulatory events. Epigenetic therapies have shown promise as single agents in the treatment of hematological malignancies but have yet to meet this expectation in solid tumors thus fostering researchers to pursue new approaches in the development and use of epigenetic interventions. Here, we review some recent pre-clinical findings involving the use of drugs targeting histone modifying enzymes both as single agents and as co-therapies against lung cancer. A greater understanding of the impact of these epigenetic compounds in lung cancer signaling is needed and further evaluation in vivo is warranted in several cases based on the pre-clinical activity of a subset of compounds discussed in this review, including drugs co-targeting HDACs and EGF receptor, targeting Brd4 and targeting Jumonji histone demethylases.

AB - Treatment options for lung cancer patients have been generally limited to standard therapies or targeted interventions which involve a small number of known mutations. Although the targeted therapies are initially successful, they most often result in drug resistance, relapse, and mortality. We now know that the complexity of lung cancer comes not only from genomic changes, but also from aberrant epigenetic regulatory events. Epigenetic therapies have shown promise as single agents in the treatment of hematological malignancies but have yet to meet this expectation in solid tumors thus fostering researchers to pursue new approaches in the development and use of epigenetic interventions. Here, we review some recent pre-clinical findings involving the use of drugs targeting histone modifying enzymes both as single agents and as co-therapies against lung cancer. A greater understanding of the impact of these epigenetic compounds in lung cancer signaling is needed and further evaluation in vivo is warranted in several cases based on the pre-clinical activity of a subset of compounds discussed in this review, including drugs co-targeting HDACs and EGF receptor, targeting Brd4 and targeting Jumonji histone demethylases.

KW - BRD4

KW - Epigenetic therapeutics

KW - EZH2 inhibitors

KW - HDAC inhibitors

KW - Jumonji demethylases

KW - Jumonji inhibitors

KW - Lung cancer

KW - Pre-clinical studies

UR - http://www.scopus.com/inward/record.url?scp=84891098436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891098436&partnerID=8YFLogxK

U2 - 10.3389/fonc.2013.00235

DO - 10.3389/fonc.2013.00235

M3 - Article

C2 - 24058902

AN - SCOPUS:84891098436

VL - 3 SEP

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - Article 235

ER -